Reata Pharmaceuticals, Inc.

Reata did not report quarterly revenue or EPS on this call. Financially, as of March 31, 2023, the company had approximately $321 million in cash, cash equivalents and marketable debt securities, excluding the newly announced $275 million debt facility. R&D expense increased by $15.7 million year over year in Q1 2023, and SG&A expense increased by $30 million year over year; on a non-GAAP basis, R&D rose by $9 million and SG&A rose by $14.1 million versus Q1 2022. The company said SKYCLARYS drug availability is expected no later than mid-August 2023, and the Pharmakon facility is expected to fund operations through the end of 2026. Management also said commercial launch economics plus the debt facility could put the company on a path to self-sustainability, with a breakeven model around approximately 1,000 SKYCLARYS patients based on current expense run-rate assumptions.

Warren Huff emphasized that SKYCLARYS is now approved as the first and only FDA-approved treatment for Friedreich’s ataxia and said early demand from patients and physicians has been strong. He framed the delay in commercial availability as a regulatory manufacturing-specification issue being worked through collaboratively with the FDA, not a change in the manufacturing process. On strategy, he highlighted pediatric expansion, Europe, and the broader Nrf2 pipeline, while saying the AYAME outcome made the decision to stop bardoxolone straightforward and allowed Reata to refocus on neurology.

Manmeet Soni focused on balance-sheet strength, stating Reata had approximately $321 million in cash, cash equivalents and marketable debt securities at March 31, 2023, before the $275 million Pharmakon financing. He said the financing will be drawn in four tranches, with the first $75 million funded that week, and that the new capital plus reduced bardoxolone spending extends runway through end-2026. He also said quarterly expenses have been running around $70 million to $75 million, or about $300 million annually, and that the company is targeting self-sustainability; he noted the total royalty burden on Omav will be 5.5% to 7.5% of net product revenues including academic institutions, Blackstone and AbbVie.

Analysts focused on three main issues: the pace of SKYCLARYS start-form growth, the FDA impurity/PAS timeline, and what the bardoxolone discontinuation means for economics and the broader pipeline. Management said 500 start forms in roughly two months was encouraging but too early to tell whether the pattern is a one-time bolus or a sustained ramp, and said 'no news is good news' on the PAS, with no added granularity from FDA beyond a prioritized review. On bardoxolone, management said the lack of ESRD separation created a regulatory problem because eGFR improvements were not sustained, while the one-off Omav royalty to Blackstone was accepted to release all bardoxolone obligations and liens.